Rivus Pharmaceuticals has released data showing the muscle-sparing benefit of its weight loss drug in a Phase IIa in obese patients with heart failure with preserved ejection fraction (HFpEF).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback